School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Data Science Centre, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Int J Clin Pharm. 2023 Feb;45(1):174-183. doi: 10.1007/s11096-022-01506-4. Epub 2022 Nov 15.
Older adults (≥ 65 years) with cancer receiving palliative care often have other health conditions requiring multiple medications.
To describe and assess the appropriateness of prescribing for older adults with cancer in the last seven days of life in an inpatient palliative care setting.
Retrospective observational study of medical records for 180 patients (60.6% male; median age: 74 years; range 65-94 years) over a two-year period. Medication appropriateness was assessed using: STOPPFrail, OncPal deprescribing guideline and criteria for identifying Potentially Inappropriate Prescribing in older adults with Cancer receiving Palliative Care (PIP-CPC).
94.5% of patients had at least one other health condition (median 3, IQR 2-5). The median number of medications increased from five (IQR 3-7) seven days before death, to 11 medications on the day of death (IQR 9-15). The prevalence of PIP varied depending on the tool used: STOPPFrail (version 1: 17.2%, version 2: 19.4%), OncPal (12.8%), PIP-CPC (30%). However, the retrospective nature of the study limited the applicability of the tools. Increasing number of medications had a statistically significant effect on risk of PIP across all tools (STOPPFrail (version 1: 1.29 (1.13-1.37), version 2: 1.30 (1.16-1.48)); OncPal 1.13 (1.01-1.27); PIP-CPC 0.70 (0.61-0.82)).
This study found that the number of medications prescribed to older adults with cancer increased as time to death approached, and the prevalence of PIP varied with the application of different tools. The study also highlights the difficulties of examining PIP in this patient cohort.
接受姑息治疗的老年癌症患者(≥65 岁)通常还有其他需要多种药物治疗的健康状况。
描述和评估在姑息治疗住院患者临终前一周内为老年癌症患者开具处方的适宜性。
对两年期间的 180 名患者(60.6%为男性;中位年龄:74 岁;范围 65-94 岁)的病历进行回顾性观察研究。使用 STOPPFrail、OncPal 去处方指南和识别接受姑息治疗的老年癌症患者潜在不适当处方的标准(PIP-CPC)评估药物适宜性。
94.5%的患者至少有另一种健康状况(中位数 3,IQR 2-5)。在死亡前七天,患者的药物中位数从 5 种(IQR 3-7)增加到死亡当天的 11 种(IQR 9-15)。根据使用的工具,PIP 的患病率有所不同:STOPPFrail(版本 1:17.2%,版本 2:19.4%)、OncPal(12.8%)、PIP-CPC(30%)。然而,研究的回顾性性质限制了工具的适用性。所有工具的研究都发现,随着临近死亡时间,药物数量的增加对 PIP 的风险有统计学显著影响(STOPPFrail(版本 1:1.29(1.13-1.37),版本 2:1.30(1.16-1.48));OncPal 1.13(1.01-1.27);PIP-CPC 0.70(0.61-0.82))。
本研究发现,随着临终时间的临近,为老年癌症患者开具的药物数量增加,而 PIP 的患病率因不同工具的应用而有所不同。该研究还突出了在这一患者群体中检查 PIP 的困难。